Surgical Treatment of Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 22
Special Issue Editor
Interests: liver surgery; liver transplantation; tumor immunology; dendritic cell immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver. Surgical treatment remains the most important treatment for HCC. Traditionally, surgical treatment is limited to treating the early stages of HCC. However, most cases of HCC are found at the late stages. Whether surgical treatment has a role in the treatment of HCC beyond the early stage is an important issue.
The tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) are applied to treat advanced HCC with promising effects. Some instances of advanced HCC can be downstaged by TKI/ICI. Thus, the treatment for HCC has changed in the ICI era. Along with the progression of medical treatments, the aspects of surgical treatment for HCC have also changed, and challenges have been raised. The role of surgical treatment in the ICI era has to be renewed.
Surgical treatment is a curative treatment for HCC. However, surgical treatment is frequently criticized for the high rate of tumor recurrence. Neoadjuvant or adjuvant treatments to supplement surgical treatment may help to improve the outcomes of surgical treatment, but effective adjuvant treatments are still lacking.
This Special Issue entitled “Surgical Treatment of Hepatocellular Carcinoma” focuses on the innovation of surgical treatments. We are pleased to invite you to submit manuscripts to this Special Issue. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: surgical techniques, surgical indications, surgical outcomes, clinical trials, liver transplantation, adjuvant therapy, basic research, etc.
We look forward to receiving your contributions.
Prof. Dr. Wei-Chen Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- surgical techniques
- surgical indications
- surgical outcomes
- clinical trials
- liver transplantation
- adjuvant therapy
- basic research
